Skip to main content

Advertisement

SpringerLink
Log in

Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Although recent studies on adults with lupus nephritis indicate that mycophenolate mofetil (MMF) may be effective in maintaining remission for patients who previously received short-term intravenous cyclophosphamide (IVCY) induction therapy, the experience with the new immunosuppressive agent in children with severe lupus nephritis has not been as satisfactory thus far. To assess the efficacy and safety of maintenance therapy with MMF, we prospectively analyzed four patients with biopsy-proven severe lupus nephritis (three girls, one boy; mean age 12 years; two with class IIIA, two with class IVG(A); mean duration of lupus nephritis 7 months) receiving MMF for at least 6 months after induction treatment. These patients had been treated previously with 6 months of low-dose IVCY combined with oral mizoribine and steroids for induction, followed by therapy with MMF adjusted to maintain predose mycophenolic acid (C0-MPA) levels at 2–5 mcg/ml. Mean follow-up after staring MMF was 27.5 months (range 6–41). The mean MMF dose required was 405 ± 49 mg/m2 per 12 h, which maintained mean C0-MPA levels of 3.3 ± 0.41 mcg/ml. No patient experienced renal flares during maintenance therapy with MMF, which permitted a significant reduction in mean prednisolone dose from 11.9 ± 1.3 to 3.9 ± 2.6 mg/day (P = 0.003). No significant gastrointestinal or hematologic side effects of MMF were noted. This preliminary study demonstrates that maintenance therapy with MMF after a low-dose IVCY regimen appears to be a promising intervention without adverse effects in children with severe lupus nephritis. These data should be confirmed by a prospective randomized multicenter clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158–166

    Article  CAS  PubMed  Google Scholar 

  2. Bartosh SM, Fine RN, Sullivan EK (2001) Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North America pediatric renal transplant cooperative study. Transplantation 72:973–978

    Article  CAS  PubMed  Google Scholar 

  3. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli G, Abzamovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 50:3934–3940

    Article  PubMed  Google Scholar 

  4. Fujinaga S, Kaneko K, Ohtomo Y, Murakami H, Takada M, Akashi S, Hira M, Yamashiro Y (2005) Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol 20:1500–1503

    Article  PubMed  Google Scholar 

  5. Jayne D (2007) Current management of lupus nephritis: popular misconceptions. Lupus 16:217–220

    Article  CAS  PubMed  Google Scholar 

  6. Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mophetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71–76

    Article  PubMed  Google Scholar 

  7. Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji YL, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN (2000) Efficacy of mycofenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162

    Article  CAS  PubMed  Google Scholar 

  8. Contreras G, Pardo V, Leclercq B, Lenz O Tozman E, O’Nan P, Roth D (2004) Sequential therapy for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  CAS  PubMed  Google Scholar 

  9. Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D (2006) Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6:121–128

    Article  CAS  PubMed  Google Scholar 

  10. Tam EM, Cohen AS, Fries J (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 35:630–640

    Google Scholar 

  11. Weening JJ, Agati DD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijin JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennete JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530

    Article  PubMed  Google Scholar 

  12. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 125:549–557

    Article  CAS  PubMed  Google Scholar 

  13. Illei GG, Austin HA, Crane M, Collinins L, Gourley MF, Yarboro CH (2001) Combination therapy with pulse cyclophosphamide plus pulse methylpredonisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248–257

    Article  CAS  PubMed  Google Scholar 

  14. Ioannidis JPA, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258–264

    Article  CAS  PubMed  Google Scholar 

  15. Moroni G, Quaglini A, Maccario M, Banfi G, Ponticelli C (1996) ‘Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50:2047–2053

    Article  CAS  PubMed  Google Scholar 

  16. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Long-term follow-up of childhood lupus nephritis. J Rheumatol 29:2635–2642

    PubMed  Google Scholar 

  17. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A (2001) Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28:2103–2108

    CAS  PubMed  Google Scholar 

  18. Paredes A (2007) Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol 22:1077–1082

    Article  PubMed  Google Scholar 

  19. Pecorario C (2005) Treatment of childhood lupus nephritis with mycophenolate mofetil: clinical and histopathological study. J Am Soc Nephrol 16:557

    Google Scholar 

  20. Adams A, MacDermott EJ, Lehman TJA (2006) Pharmacotherapy of lupus nephritis in children. Drug 66:1191–1207

    Article  CAS  Google Scholar 

  21. Moudgil A, Bagga A, Jordan SC (2005) Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol 20:1376–1381

    Article  PubMed  Google Scholar 

  22. Langman LJ, Legatt DF, Halloran PF, Yatscoff RW (1996) Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 62:666–672

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Saitama Children’s Medical Center, 2100 Magome, Iwatsuki-ward, Saitama-city Saitama, 339 8551, Japan

    Shuichiro Fujinaga & Satoshi Hara

  2. Department of Pediatrics, Juntendo Nerima Hospital, 3–1–10 Takanodai, Nerima-ku, Tokyo, 117–8521, Japan

    Yoshiyuki Ohtomo

  3. Department of Pediatrics, Juntendo University School of Medicine, 2–1–1 Hongo, Bunkyo-ku, Tokyo, 113–8421, Japan

    Daisuke Umino, Tomonosuke Someya & Toshiaki Shimizu

  4. Department of Pediatrics, Kansai Medical University, 10–15 Fumizono-cho, Moriguchi-city, Osaka, 570–8506, Japan

    Kazunari Kaneko

Authors
  1. Shuichiro Fujinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiyuki Ohtomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Umino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomonosuke Someya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshiaki Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazunari Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichiro Fujinaga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujinaga, S., Ohtomo, Y., Hara, S. et al. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol 23, 1877–1882 (2008). https://doi.org/10.1007/s00467-008-0800-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-008-0800-7

Keywords

Search

Navigation